| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 11 | 2018 | 300 | 2.360 |
Why?
|
| Lung Neoplasms | 13 | 2021 | 1172 | 1.840 |
Why?
|
| Immunotherapy | 4 | 2018 | 215 | 1.080 |
Why?
|
| Interleukin-15 | 3 | 2022 | 66 | 1.080 |
Why?
|
| Interleukin-2 | 3 | 2018 | 133 | 0.880 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 266 | 0.830 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2021 | 66 | 0.830 |
Why?
|
| Circulating MicroRNA | 1 | 2020 | 9 | 0.740 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 21 | 0.740 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 467 | 0.710 |
Why?
|
| Azacitidine | 4 | 2020 | 20 | 0.660 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2022 | 87 | 0.640 |
Why?
|
| Adoptive Transfer | 2 | 2018 | 100 | 0.610 |
Why?
|
| DNA Methylation | 7 | 2021 | 193 | 0.580 |
Why?
|
| MicroRNAs | 1 | 2020 | 447 | 0.520 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 160 | 0.510 |
Why?
|
| B7-H1 Antigen | 4 | 2020 | 30 | 0.490 |
Why?
|
| Proteins | 1 | 2018 | 473 | 0.480 |
Why?
|
| Cysteine Dioxygenase | 1 | 2014 | 1 | 0.480 |
Why?
|
| Tachykinins | 1 | 2014 | 8 | 0.480 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 597 | 0.450 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 77 | 0.450 |
Why?
|
| Neoplasms | 3 | 2021 | 1664 | 0.450 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 157 | 0.440 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2021 | 624 | 0.430 |
Why?
|
| Melanoma | 3 | 2022 | 335 | 0.420 |
Why?
|
| Biomarkers, Tumor | 6 | 2018 | 508 | 0.390 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2022 | 376 | 0.320 |
Why?
|
| Battered Women | 1 | 2008 | 15 | 0.310 |
Why?
|
| Cultural Characteristics | 1 | 2008 | 42 | 0.310 |
Why?
|
| Spouse Abuse | 1 | 2008 | 40 | 0.310 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 799 | 0.300 |
Why?
|
| Melanoma, Experimental | 2 | 2019 | 95 | 0.300 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 375 | 0.290 |
Why?
|
| Humans | 27 | 2022 | 68549 | 0.290 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 52 | 0.290 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 561 | 0.280 |
Why?
|
| Retinoids | 1 | 2007 | 122 | 0.270 |
Why?
|
| DNA | 3 | 2021 | 597 | 0.250 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 163 | 0.230 |
Why?
|
| Mouth Neoplasms | 2 | 2021 | 206 | 0.230 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2018 | 132 | 0.210 |
Why?
|
| Genetic Therapy | 3 | 2020 | 291 | 0.200 |
Why?
|
| Mass Screening | 1 | 2008 | 838 | 0.200 |
Why?
|
| Healthy Volunteers | 1 | 2022 | 78 | 0.200 |
Why?
|
| Aged | 11 | 2022 | 14842 | 0.200 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 213 | 0.190 |
Why?
|
| Immunoconjugates | 1 | 2021 | 26 | 0.190 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 1851 | 0.190 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 439 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 21 | 0.180 |
Why?
|
| Benzamides | 3 | 2020 | 156 | 0.180 |
Why?
|
| Amino Acid Transport Systems | 1 | 2019 | 3 | 0.180 |
Why?
|
| Middle Aged | 11 | 2021 | 21119 | 0.170 |
Why?
|
| Symporters | 1 | 2019 | 27 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 28 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2019 | 35 | 0.170 |
Why?
|
| Pyridines | 3 | 2020 | 261 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 444 | 0.160 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2018 | 10 | 0.160 |
Why?
|
| HLA-DR Antigens | 1 | 2018 | 41 | 0.160 |
Why?
|
| Signal Transduction | 2 | 2019 | 2689 | 0.150 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2017 | 7 | 0.150 |
Why?
|
| Female | 13 | 2021 | 38021 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 332 | 0.150 |
Why?
|
| Interleukin-7 | 1 | 2017 | 18 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 307 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 38 | 0.140 |
Why?
|
| Th17 Cells | 1 | 2017 | 116 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2016 | 110 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 536 | 0.130 |
Why?
|
| Male | 11 | 2021 | 37283 | 0.120 |
Why?
|
| United States | 4 | 2022 | 7338 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2015 | 228 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2021 | 7028 | 0.120 |
Why?
|
| Neutrophils | 1 | 2015 | 204 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 614 | 0.120 |
Why?
|
| CpG Islands | 1 | 2014 | 51 | 0.120 |
Why?
|
| HIV Seropositivity | 1 | 2014 | 65 | 0.120 |
Why?
|
| Epigenomics | 1 | 2013 | 29 | 0.110 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 349 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 1070 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 560 | 0.110 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2012 | 1 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 1753 | 0.100 |
Why?
|
| Lymphoma, Primary Effusion | 1 | 2012 | 7 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 492 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 194 | 0.100 |
Why?
|
| Herpesvirus 8, Human | 1 | 2012 | 24 | 0.100 |
Why?
|
| Sarcoma, Kaposi | 1 | 2012 | 24 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 791 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2012 | 114 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2012 | 79 | 0.100 |
Why?
|
| Lung | 1 | 2016 | 849 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2013 | 682 | 0.100 |
Why?
|
| Prognosis | 4 | 2018 | 2093 | 0.090 |
Why?
|
| Animals | 6 | 2020 | 20880 | 0.090 |
Why?
|
| Apoptosis | 1 | 2017 | 1641 | 0.090 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.090 |
Why?
|
| Medicare | 2 | 2022 | 316 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 951 | 0.080 |
Why?
|
| Smoking | 2 | 2014 | 1449 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 151 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 306 | 0.080 |
Why?
|
| Georgia | 1 | 2008 | 161 | 0.080 |
Why?
|
| Communication Barriers | 1 | 2008 | 48 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2007 | 26 | 0.070 |
Why?
|
| Women's Health | 1 | 2008 | 148 | 0.070 |
Why?
|
| Urban Population | 1 | 2008 | 254 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2022 | 7268 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2021 | 2356 | 0.070 |
Why?
|
| Mice | 4 | 2020 | 8474 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 775 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 848 | 0.050 |
Why?
|
| Histones | 2 | 2015 | 111 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2022 | 45 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 2004 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 104 | 0.050 |
Why?
|
| Benzodiazepinones | 1 | 2021 | 4 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 10 | 0.050 |
Why?
|
| Adult | 4 | 2018 | 21379 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1549 | 0.050 |
Why?
|
| Receptors, CCR2 | 1 | 2020 | 9 | 0.050 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2020 | 9 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2021 | 124 | 0.040 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1999 | 6 | 0.040 |
Why?
|
| Phosphopeptides | 1 | 1999 | 8 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 129 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 714 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2798 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 32 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 304 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 59 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 447 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 34 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2007 | 1032 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 39 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1999 | 317 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 91 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 756 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 630 | 0.040 |
Why?
|
| Sputum | 1 | 2016 | 51 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 199 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 539 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 397 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 238 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 53 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 1213 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1034 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1174 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 392 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 226 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1027 | 0.030 |
Why?
|
| Transcriptome | 1 | 2016 | 164 | 0.030 |
Why?
|
| Camptothecin | 1 | 2015 | 39 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 160 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 138 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 137 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 238 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 498 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 981 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 98 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 170 | 0.030 |
Why?
|
| Sulfites | 1 | 2013 | 7 | 0.030 |
Why?
|
| Microspheres | 1 | 2013 | 59 | 0.030 |
Why?
|
| Pulmonary Emphysema | 1 | 2014 | 71 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2013 | 237 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 1055 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1174 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 2550 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2012 | 12 | 0.030 |
Why?
|
| Methylation | 1 | 2012 | 56 | 0.030 |
Why?
|
| Actins | 1 | 2013 | 249 | 0.030 |
Why?
|
| Maryland | 1 | 2012 | 77 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 901 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2012 | 58 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 2791 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1293 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 770 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 929 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1582 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1609 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1860 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 955 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1037 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1425 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 3703 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2324 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 5720 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1615 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 4843 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 230 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 1999 | 147 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 241 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1999 | 250 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1999 | 765 | 0.010 |
Why?
|
| Swine | 1 | 1999 | 672 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 1082 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 1446 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1999 | 1200 | 0.010 |
Why?
|